Stryker Reports Higher 4Q Profit, Sales but EPS Misses Wall Street Target

   By Maria Armental 
 

Stryker Corp. reported higher fourth-quarter profit and sales, but per-share earnings missed Wall Street's target.

Profit for the medical technology products and services company rose to $662 million from $568 million a year earlier. On a per-share basis, profit was $1.73, or $2.71 as adjusted. Analysts surveyed by FactSet expected $2.48 a share, or $2.72 a share as adjusted.

The results included $137 million in asset impairments, primarily in-process research and development along with plant and equipment as a result of pandemic-related demand impacts on in-process product development and other divestiture and restructuring activities, the company said.

Net sales for the quarter rose to $4.7 billion from $4.26 billion a year earlier. Analysts expected $4.65 billion in revenue.

The company ended the year with a $2 billion profit on $17.11 billion in sales, compared with a profit of $1.6 billion and $14.35 billion in sales a year earlier.

Chief Executive Kevin Lobo had said that the resurgence of Covid-19 cases had largely affected Stryker's U.S. implant-related businesses with scheduled procedures being deferred. On Thursday, Mr. Lobo said the company delivered a strong year of financial results, despite the challenges of the pandemic.

Write to Maria Armental at [e-mail]

(END) Dow Jones Newswires

January 27, 2022 16:34 ET (21:34 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.